论文部分内容阅读
目的探讨替尼泊甙（ＶＭ－２６）为主的化疗方案相伴放疗治疗小细胞肺癌的临床疗效。方法５３例小细胞肺癌中，４８例选用ＶＭ－２６＋顺铂（ＤＤＰ）方案，ＶＭ－２６每天６０ｍｇ／ｍ２，ＤＤＰ每天２５ｍｇ／ｍ２，连用３天为一个疗程；另５例用卡铂取代ＤＤＰ，５００ｍｇ静脉滴注，１天完成。除第１个与第２个疗程化疗间隔４０天左右外，以后每４周重复１个疗程，共５个疗程。在第１个疗程化疗后１～４天内开始放射治疗。对局限期和广泛期患者分别照射不同的剂量和部位。结果局限期患者近期疗效为９７．８％［完全缓解（ＣＲ）为５３．３％，部分缓解（ＰＲ）为４４．８％］，１年和２年生存率分别为７７．１％（２７／３５）和４４％（１１／２５），中位生存期大于１８个月。广泛期患者近期疗效为７５％（ＣＲ２５％），一年生存率为３７．５％（３／８），中位生存期大于１１个月。结论以ＶＭ－２６为主的化疗方案相伴放疗是治疗小细胞肺癌的有效方案，可提高肿瘤的局部控制率。
Objective To investigate the clinical efficacy of the chemotherapy regimen based on teniposide (VM-26) combined with radiotherapy for small cell lung cancer. Methods Among 53 cases of small cell lung cancer, 48 cases were treated with VM-26+cisplatin (DDP), VM-26 was given at 60mg/m2 daily, DDP was given at 25mg/m2 daily for 3 days as a course of treatment. The other 5 patients were treated with carboplatin instead of DDP. , 500mg intravenous infusion, completed in 1 day. In addition to the 40-day interval between the first and second courses of chemotherapy, a course of treatment is repeated every 4 weeks for a total of 5 courses. Radiotherapy was started within 1 to 4 days after the first course of chemotherapy. Patients with limited and extensive periods were exposed to different doses and sites. Results The short-term efficacy of the patients in the phase-limited period was 97.8% [53.3% for complete remission (CR), 44.8% for partial remission (PR)], and the 1-year and 2-year survival rates were 77.1%, respectively (27 / 35) and 44% (11/25), with a median survival of more than 18 months. The short-term efficacy of extensive patients was 75% (CR25%), the one-year survival rate was 37.5% (3/8), and the median survival was greater than 11 months. Conclusion VM-26-based chemotherapy combined with radiotherapy is an effective treatment for small cell lung cancer, which can increase the local control rate of tumors.